GB2191482A - Substituted pyrimidoindoles and diazepinoindoles - Google Patents

Description

GB2191482A 1

SPECIFICATION

Substituted pyrimidoindoles and diazepinoindoles 5 This invention relates to substituted pyrimidoindoles and diazepinoindoles, to processes for their preparation, to their use and to pharmaceutical compositions containing them.

The novel compounds of the present invention are compounds of the general formula (1) R1 R NR5R6 10 N --, (I) N X R2 15 and their pharmaceutical ly acceptable acid addition salts. In the formula. R represents alkyl or a mono-or bicyclic aryl radical, R' and R2 which may be the same or different each represent hydrogen, hydroxyl, lower alkyl, lower alkoxy, halo(lower)aikyi, halogen, amino or mono-or di( lower)alkylamino, X represents -CH,CR3R4C1-12- or -(CH,),- where R3 and R4 each independently 20 represent hydrogen or lower alkyl or R3 and R4 together with the carbon atom to which they are attached represent a 5,6 or 7 membered carbocyclic ring and R5 represent acyl and R6 repre sents hydrogen or R5 and R6 each independently represent hydrogen or lower alkyl.

The term---lower-as used herein means that the radical referred to contains 1 to 6 carbon atoms. For example, a lower alkyl group may be methyl, ethyl, propyl or butyl and a lower 25 alkoxy may methoxy, ethoxy, propoxy or butoxy.

The term---aryl- is used herein to denote a radical having an aromatic character. Such radicals include phenyl, naphthyl and heterocyclic radicals having an aromatic character. For example, when R is an aryl radical it may be a radical such as phenyl, naphthyl, thienyl, pyridyl, indolyl and benzothienyl, each of which may be substituted or unsubstituted. Suitable substituents 30 include those mentioned herein for the definitions of R' and R2; preferable substituents are halogen (for example fluorine, chlorine or bromine), lower alkyl (for example methyl, ethyl, propyl or butyl), lower alkoxy (for example methoxy, ethoxy, propoxy or butoxy) and halo(lower)alkyl (for example trifluoromethyl). Preferably R is phenyl optionally substituted as mentioned above.

Preferred examples of R' and R2 residues include hydrogen, lower alkyl (e. g. methyl, ethyl, 35 propyl and butyl), lower alkoxy (e.g. methoxy, ethoxy, propoxy and butoxy, halo(lower)aikyl (e.g.

trifluoromethyl) and halogen (e.g. chlorine and bromine).

Preferably R3 and R4 are both hydrogen or both lower alkyl (e.g. methyl). R3 and R4 together with the carbon atom to which they are attached can also represent a cycloalkyl radical contain- ing 5 to 7 carbon atoms (e.g. cyclohexyl). 40 R5 and R6 are preferably both hydrogen or one is hydrogen and the other is an acyl group.

The acyl group may be derived from a carboxylic acid or other acid such as a sulphonic acid or a sulphonylcarbamic acid. For example the acyl group may be (lower) alkoxycarbony], lower alky] or aryl- or a ryl (lower)al kylsul phony], lower alkyl- or aryl- or aryl(iower)aiky[sulphonylcarbamoyI or preferably lower alkylcarbonyl, arylcarbonyl or aryi(iower)aikylcarbonyl where the aryi group is 45 preferably phenyl optionally substituted as mentioned above. A particularly preferred acyl group is (lower) alkylca rbo nyl.

The compounds of the invention in which R5 represents a (lower)alkylcarbonyl group and R6 represents hydrogen are amides which may be prepared by reacting a tertiary alcohol of general formula 50 R' R OH N N X (11) 55 R2 (where X, R, R' and R2 are as defined above) or an acid addition salt thereof, with an organic 60 nitrile of general formula R7CN (111) where R' represents lower alkyl. The tertiary alcohol or the salt thereof may be reacted with the nitrile in the presence of a strong acid (e.g. concentrated sulphuric acid, phosphoric acid or 65 2 GB2191482A 2 polyphosphoric acid) as in the Ritter reaction (1.1. Krimen and D.J.Cota, Organic Reactions, 1969,17, 213). The resulting amide may be obtained by dilution of the reaction mixture with water.

The other compounds of the invention may be obtained from the compounds in which R5 represents a (lower)aikylearbonyl group and R6 represents hydrogen. For example the compound 5 may be hydrolysed (e.g. under acid conditions) to give the primary amine of general formula (1) in which R5 and R6 are both hydrogen. The primary amine may be mono-or di-N- alkyiated by methods known in the art to give compounds in which R5 is lower alkyl and R6 is hydrogen or lower alkyl. The amine may also be acylated to give compounds of the invention in which R5 represents acyl and R6 represents hydrogen. The acylating agent may be an acid anhydride (e.g. 10 acetic anhydride), an acyl halide such as an alkanoyl chloride (e.g. acetyl chloride), an aroyl chloride (e.g. benzoyl chloride), a sulphonyl chloride (e.g. methane sulphonyl chloride or toluene sulphonyl chloride) or a sulphonyl isocyanate (e.g. toluenesulphonyl isocyanate).

The tertiary alcohols of the general formula Ill may be prepared by, for example, reacting a ketone of general formula 15 R1 0 N - G V) 20 X R2 (where R, R2 and X have the meanings given above) with an organic metallic compound, such 25 as a Grignard reagent, containing the R residue. This process is exemplified in our UK Specifica tion 1,366,133.

If in the process described above the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt.

Conversely, if the product of the process is a free base, an acid addition salt, particularly a 30 pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.

Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, 35 methanesulphonic and p-toluenesulphonic acids.

The compounds of the invention possess at least one asymmetric carbon atom and hence can exist in various stereochemical forms. The stereochemical forms can be separated or isolated by standard procedures. For example resolution of a racemic final product or intermediate may be carried out by known procedures so as to give the product as an optically active enantiomorph. 40 The compounds of the present invention possess pharmacological activity. For example, the compounds in general possess hypoglycaemic activity and hence are of value in the treatment of diabetes. The compounds of the invention are tested for hypoglycaemic activity by a standard procedure in which the compounds are administered to rats and the blood glucose concentration is determined prior to administration and at various times after dosage. When 10-amino2,3,4,10-tetrahydro-3,3-dimethy]-10-phenylpyrimido[1,2-al-indole, a representative compound of the invention, was tested by this procedure at 100 mg/kg p.o. the blood glucose concentration was found to be 68% of that of control animals (i.e. rats administered vehicle alone) at 4 hours after administration.

The invention further provides a compound of formula (1) or a pharmaceutically acceptable acid 50 addition salt for use as a hypogiycaemic in a mammal.

The invention also provides a pharmaceutical composition comprising a compound of general formula (1) or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In such a composition, the carrier is generally a solid or liquid or 55 a mixture of a solid and a liquid.

Solid form compositions include powders, granules, tablets, capsules (e.g. hard and soft gelatine capsules), suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids, binders or ta blet-disinteg rating agents; it can also be an 60 encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, e.g. from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium 65 3 GB2191482A 3 phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion ex change resins.

The term -composition- is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without 5 other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.

Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions. The active ingredient, for example, can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a 10 mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeten ers, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabil isers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administra tion include water (particularly containing additives as above e.g. cellulose derivatives, preferably 15 sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycerol and glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. 20 Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. 25 In such form the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The quantity of the active ingredient in unit dose of composition 30 may be varied or adjusted from 0.5 mg or less to 750 mg or more, according to the particular need and the activity of the active ingredient. The invention also includes the compounds in the absence of the carrier where the compounds are in unit dosage form.

The following Examples illustrate the invention:

35 EXAMPLE 1

10-Acetamido- 10-(3-chlorophenyl)-2,3,4, 10-tetrahydropyrimido[ 1,2alindole Concentrated sulphuric acid (12 mi) was added dropwise over 5 minutes to vigorously stirred acetonitrile (24 m]) at 0-5'. The resulting colourless solution was treated in one portion with 10(3-chlorophenyi)-2,3,4,10-tetrahydropyrimido[1,2-a]indol-10-oI (3.09). The mixture was immedi- 40 ately stirred and heated at 50-60' whereupon solution occured within 5 minutes. After 1 hour, the solution was poured onto ice (100 mi) and the mixture was basified with saturated aqueous ammonia (90 m]) and extracted with dichloromethane (3x60 mi). The extracts were dried (M9S04) and evaporated in vacuo. The residue was triturated with ethyl acetate to give light brown crystals which were purified by flash chromatography (A1103, ethyl acetate), trituration 45 with ethanol-ether (1:1), and washing with ether to give the title compound free base as a colourless powder.

The free base was dissolved in dichloromethane-methanol (4:1) and acidified with ethereal HCI to give the title compound as the hydrochloride (0.19g), m.p. 275-285' (dec.).

Found: C, 593; H, 5. 1; N, 11.0% 50 Cl,H,,CIN,O.HCI.IH,0 requires C, 59.9; H, 5.1; N, 11.0%.

4 EXAMPLE 2

1 0-A mino- 10-(3-chlorophenyl)-2,3,4, 10 ' tetrahydropyrimido-[ 1,2alindole A solution of the product of Example 1 (2.48g) in hydrochloric acid 36% w/w (10 mi) was 55 2 b (50 mi), heated at 120' with stirring for 21 hours, cooled to room temperature, diluted with H2 washed with ethyl acetate (3 X 50 MI), basified with 33% aqueous ammonia and extracted with chloroform (3x100 mi). The extracts were washed with brine (100 m]), dried (MgSOJ and evaporated in vacuo. The oil was dissolved in methanol (10 m]), acidified with ethereal HCI, and evaporated in vacuo to give a solid which was triturated with ether (3 x 10 ml) to give the title 60 compound as the hydrochloride (1.839) as colourless crystals, m.p. 274- 276' (dec.).

Found: C, 55.1; H, 4.8; N, 10.95% C,,H,,C]N3.2HCI requires C, 55.1; H, 4.9; N, 11.3%.

EXAMPLE 3 65

GB2191482A 4 10-Acetamido-2,3,4, 10-tetrahydro10-phenylpyrimido-[1,2-alindole A solution of 2,3,4,10-tetrahydro-10-phenylpyrimido-[1,2-alindol-10-ol (7. 159) in acetonitriie (50 ml) and methanesulphonic acid (3 mi) was added dropwise with caution over 25 minutes to a pre-heated flask containing stirred sulphuric acid 98% w/w (28 mi) at such a rate that the temperature remained steady at 51-56'. The solution was cooled to room temperature, poured 5 into water (200 mi) and basified with sodium hydroxide (40 9) and sodium carbonate. The mixture was extracted with chloroform (3x200 m]) and the extracts washed with brine (50 mi), dried (M9S04), and evaporated in vacuo. The yellow solid was triturated with ethyl acetate to give a first crop of the product free base (2.7359) as a colourless powder. The triturates were purified by chromatography (A1,0,; ethyl acetate) to give a second crop of the product free base 10 (1.169) also as a colourless powder.

The first crop of the product free base was suspended in methanol (8 mi), acidified with ethereal HQ, and the resulting solution evaporated in vacuo to give an oil which on trituration with ethyl acetate and ether gave the title compound as the hydrochloride (3.01g), m.p.

315-325' (dec.). 15 Found: C, 66.3; H, 6. 1; N, 12.5% C,,H,,N30.HCI requires C, 66.75; H, 5.9; N, 12.3%.

EXAMPLE 4

10-Amino-10-phenyl-2,3,4, 10-tetrahydropyrimido[1,2-alindole 20 A solution of the product of Example 3 (1.019) in hydrochloric acid 36% w/w (15 mi) was heated with stirring at 110 for 5 hours. The mixture of liquid and precipitate was cooled to room temperature, dissolved in water (40 mi), washed with ethyl acetate (2 x 100 mi), basified with 33% aqueous ammonia, extracted with dichloromethane (2 x 100 mi) and the extracts washed with brine (50 mi), dried (M9SOJ, and evaporated in vacuo to give the title compound 25 as a free base. The solid was suspended in methanol (5 m]), acidified with ethereal hydrochloric acid, and the resulting solution evaporated in vacuo to give the crude product as a dihydrochlo ride. The product was recrystallised from methanol-ethyl acetate to give two crops of product:

Crop A as colourless crystals (0.499), m.p. 260-265' (dec.) Found: C, 603; H, 6.0; N, 12.2% 30 C,7H,N,21---1C1 requires C, 603; H, 5.7; N, 12.5% and Crop B as colourless crystals (0.22g), m.p. 260-265' (dec.) Found: C, 60.2; H, 6.1; N, 11.9% Calculated for C,71---117N3.21---ICIAH,O:C, 59.9; H, 5.8; N, 12.3%.

4 35 EXAMPLE 5

10-Acetamido-2,3,4, 10-tetrahydro-3,3-dimethyl- 10-phenylpyrimido[ 1,2alindole A solution of 2,3,4, 1 0-tetra hydro- 1 0-phenyl pyrimido [1,2-alindol-10- ol (10.38g) in acetonitrile (75 mi) and methane-sulphonic acid (4.2mi) was added dropwise with judicious cooling over 40 min to a pre-heated flask containing stirred sulphuric acid 98% wlw (38mi) at such a rate that 40 the temperature remained steady at 50-55'. The solution was cooled to room temperature, poured into water (600mi), and basified with sodium hydroxide (50g, 1. 25mol) and sodium carbonate. The mixture was extracted with chloroform (3 X 350mi) and the combined extracts were washed with water (350mi), dried (M9S04), and evaporated in vacuo to give the title compound as a colourless solid (10.03g). 45 The sample was converted into the hydrochloride salt, m.p. >300' Found: C, 66.9; H, 6.65; N, 11.2 C,,H,,N,O.HCI. 1. H,0 requires C, 66.6; H, 6.65; N, 11. 1 % 2 EXAMPLE 6 50

10-Amino-2,3,4, 10-tetrahydro-3,3-dimethyl- 10-phenylpyrimido[1,2alindole A solution of the product free base from Example 5 (7.76g) in hydrochloric acid 36% W1w (35mi) was heated with stirring at 110' for 3.5 h, cooled to room temperature, dissolved in water (350mi), basified with 33% aqueous ammonia, extracted with chloroform (2x200mi) and the extracts washed with water (350mi), dried (M9SOJ, and evaporated in vacuo to give the 55 title compound as a free base (4.139). A sample of the free base was converted into the dihydrochloride salt, m.p. 260-265' (dec).

Found: C, 62.0; H, 6.3; N, 11.2 Cl,H,,N,.2HCI.!H20 requires C, 61.9; H, 6.4; N, 11.4%.

4 60 EXAMPLE 7

10-Acetamido-2,3,4, 10-tetrahydro- 10-methylpyrimido[ 1,2-alindole A solution of 2,3,4,10-tetrahydro-10- ' methylpyrimido[1,2-alindol-10-oJ (0.4449) in acetonitrile (4mi) and methanesulphonic acid (10 drops) was added dropwise over 5 min to stirred sulphuric acid 98% w/w (2.5mi) at 50-60'. After 2.5h, the solution was poured into water (100mi), 65 GB2191482A 5 basified with sat. aqueous sodium bicarbonate, and extracted with chloroform (3 x 1 00mi). The extracts were washed with water (200 m]), dried (M9S04), and evaporated in vacuo to give the title compound as the free base (0.07g).

The hydrochloride of the title compound was prepared from methanol-ether as hygroscopic brown crystals, m.p. 255-260'(dec.). 5 Found: C, 573; H, 6.8; N, 14.2 C14H,7N3O.HCI.-IH20 requires C, 57.3; H, 63; N, 14.3%.

4 EXAMPLE 8

2,3,4, 10-Tetrahydro-3,3dimethyl- 10-methylsulphonylamino- 10phenylpyrimido[1,2-alindole 10 Methanesulphonyl chloride (1 mi) was added to the product free base from Example 6 (1.209) in dry pyridine (50 m[). After 1 hour the solution was evaporated in vacuo and the residual oil dissolved in dichloromethane (50mi), washed with water (50mi), saturated aqueous sodium bicarbonate (50mi), and water (50mi), dried (M9S04), evaporated in vacuo, and purified by chromatography (A1201; ethyl acetate to give the free base of the title product as a brown solid 15 (0.399).

The hydrochloride salt, m.p. 160-165' (dec) was prepared from ethermethanol.

Found: C, 57.0; H, 6.0; N, 9.9 C20H2,N,O,S.HCI.2H20 requires C, 57.3; H, 6.1; N, 10.0% 4 20 EXAMPLE 9

10'-Acetamido-2',3',4'10'-tetrahydro- 10-phenylspiro[cyclohexane- 1,3'pyrimido[1,2-alindolel A solution of 10'-hydroxy-10'-phenyi-2',3',4',10'tetrahydrospiro[cyclohexane-1,3'-pyrimid o[1,2- alindole] hydrochloride (1.073g), in acetonitrile (10mi) and methanesulphonic acid (90 drops) was added dropwise over 20 min to sulphuric acid 98% w/w (4mi) at 45-55' with stirring. After 1 25 hour, the solution was poured into water (100mi) and the mixture was basified with 1N-sodium hydroxide and extracted with chloroform (3 x 1 00mi). The extracts were washed with water (100 mi), dried (M9S04), and evaporated in vacuo to give a solid. The solid was dissolved in methanol and the solution acidified with ethereal HCl and evaporated in vacuo to give the title compound as the hydrochloride (0.06g), m.p. >30W. 30 Found: C, 67.65; H, 7.0; N, 9.5.

C24H2,N3O.HCL.H20 requires C, 67.4; H, 7.1; N, 9.8%.

EXAMPLE 10

1 1-Acetamido-2,3,4,5-tetrahydro- 1 1-phenyl- 1 1H-[ 1,3]diazepino[ 1,2alindole 35 A suspension of 2,4,5,1 1-tetrahydro-l 1-phenyl-3H-[1,3]diazepinoi[1,2- alindol-1 1-ol hydrobrom ide (2.899) in acetonitrile (16mi) and methanesulphonic acid (100 drops) was added dropwise over 10 min to stirred sulphuric acid 98% w/w (8mi) at 50-60'. After 1 hour, the solution was 2 cooled to room temperature, poured into water (200mi), basified with sodium hydroxide (10g) and sodium carbonate and extracted with chloroform (2x200mi). The extracts were dried 40 (M9S04) and evaporated in vacuo. The brown oil was purified by chromatography (A1201; ethyl acetate) to give the product free base (0.829) as a colourless solid. The hydrochloride was prepared from ether-methanol as a solid (1.06g), m.p. 285-290' (dec.).

Found: C, 64.5; H, 6.2; N, 11.3.

C2,H2,N,O.HCI.H20 requires C, 64.25; H, 6.5; N, 11.2%. 45 EXAMPLE 11

10-Acetamido-2,3,4, 10-tetrahydro- 10-(2-naphthyl)pyrimido[ 1,2-alindole 10-(2-Naphthyl)-2,3,4,10-tetrahydropyrimdo [1,2-a]indol-10-ol hydrochloride (1.89g) in acetoni trile (12mi) and methanesulphonic acid (120 drops) was added dropwise over 15 min to sul- 50 phuric acid 98 w/w (6mi) with stirring at 54-64'. After 1 hour, the solution was cooled to 2 room temperature, poured into water (200mi), and basified with sodium hydroxide (7.5g) and sodium carbonate. The precipitate was filtered, washed with water (2x50mi), and air-dried to give a brown solid (0.65g). The filtrate was extracted with chloroform (2x200mi) and the extracts dried (MgSOJ and evaporated in vacuo to give an oil (0.47g).The solid and the oil were 55 combined and purified by chromatography (A1203; ethyl acetate) to give the product free base (0.34g) as a foam. The foam was dissolved in methanol (lml) and the solution acidified with ethereal HO (5m1) and evaporated in vacuo to give a foam which was induced to crystallise by trituration with ethyl acetate to give the title compound as the hydrochloride (0.319), m.p.

265-268 (dec). 60 Found: C, 69.9; H, 5.75; N, 10.9.

C2,H2,N,O.HCI.!H20 requires C, 693; H, 5.7; N, 10.6%.

4 EXAMPLE 12

10-Acetamido-2"3',4'10-tetrahydro-10-phenylspiro[cyclopentane-1,3-pyrimi do[1,2-alindolej 65 6 GB2191482A 6 2',XA', 1 W-Tetrahydro- 1 W-hydroxy- 1 O-phenyispiro[eyclopentane- 1,Y- pyrimido[ 1,2-a]indolel (29)in acetonitrile (16mi) and methanesulphonic acid (100 drops) was added dropwise over 10 min to sulphuric acid 98% w/w (8mi) at 50-60' with stirring. After 1 hour the solution was 2 cooled to room temperature, poured into water (200mi), and basified with 1M-sodium hydroxide.

The mixture was extracted with chloroform (2x200mi) and the extracts dried (M9SOJ and 5 evaporated in vacuo to give a solid which was purified by chromatography [A1203; chloroform methanol (100:1)]. The yellow solid was dissolved in methanol (2mi), acidified with ethereal HQ (5ml), and evaporated in vacuo to give a glass. Trituration with ethyl acetate gave the title compound as the hydrochloride (0.59), m.p. >30W.

Found: C, 69.2; H, 6.8; N, 10.2. 10 C23H2,N,O.HCI.!H20 requires 69.0; H, 6.7; N, 10.5%.

4 EXAMPLE 13

10-Butanamido-2,3,4, 10-tetrahydro-3,3-dimethyl- 10-phenylpyrimido[ 1,2alindole 2,3,4,10-Tetrahydro-10-phenylpyrimido[1,2-a]indol-10-ol (2.199) in butyronitrile (16mi) and 15 methanesulphonic acid (100 drops) was added dropwise over 10 min to sulphuric acid 98% w/w (8mi) at 50-600 with stirring. After 1 hour, the solution was poured into water (200mi), basified with 1N-sodium hydroxide, and extracted with chloroform (2x200mi). The extracts were washed with 1M-sodium hydroxide (100mi) and water (100mi), dried (MgSOJ, and evaporated in vacuo to give the product free base as a solid (0.679). The solid was dissolved in methanol 20 (2mi), acidified with ethereal-HCI (5m]), and evaporated in vacuo to give the title compound as the hydrochloride (0.69), m.p. 275-280' (dec).

Found: C, 68.9; H, 7.3; N, 10.2.

C2,H17N,O.HCI.I-H20 requires C, 683; H, 7.1; N, 10.4%.

4 25 EXAMPLE 14

2,3,4,10-Tetrahydro-3,3-dimethyl-10-[3-(4-methylphenyisulphonyl)ureido]10ph enylpyrimido[1,2- alindole 4-Toluenesulphonyl isocyanate (1.0g) in acetonitrile (5mi) was added dropwise to a stirred solution of the product free base from Example 6 (1.179) in acetonitrile (50mi). After 1 hour, the 30 solution was evaporated in vacuo to give a glass which was induced to crystallise by trituration with ethyl acetate-methanol (5A, 6mi). The solid was suspended in methanol (30mi) and ether eal-HCI (4mi) added. A solution was formed from which a solid precipitated after a few minutes.

The solid was filtered, washed with ether, and dried in vacuo to give the title compound as the hydrochloride (1.699), m.p. 253-255' (dec.) 35 Found: C, 61.5; H, 53; N, 10.5.

C27H2,N,SO,.HCI requires C, 61.8; H, 5.6; N, 10.7% EXAMPLE 15

10-Benzamido-2,3,4, 10-tetrahydro-3,3-dimethyl- 10-phenylpyrimido[ 1,2alindole 40 Benzoyl chloride (0.9mi) was added dropwise to the product free base from Example 6 (1.12g) in triethylamine (lmi)-pyridine (40mi). After 1 hour, the solution was evaporated in_vacuo. The residue was azeotroped in vacuo with toluene (50mi) and dissolved in dichloromethane (50 mi).

The solution was washed with water (2 x 1 00mi), dried (MgSOJ, and evaporated in vacuo to give a yellow foam which crystallised from ether-dichloromethane (1:1). The solid was recrystal- 45 lised from ethyl acetate-cyclohexane to give a first crop of the product (0.59g), m.p. 183-185'.

The filtrate was purified by chromatography (A1201; ether) and trituration with ether to give a second crystalline crop of the product (0.709). The two crops of the free base were combined, suspended in methanol (5m]), and acidified with ethereal HCL The solution was evaporated in vacuo to give a glass which crystallised from boiling ethyl acetate as the title compound 50 hydrochloride (0.999), m.p. 295-298' (dec.) Found: C, 72.4; H, 6. 1; N, 9.4.

C2,H2,N,O.HCI requires C, 72.3; H, 6. 1; N, 9.7%.

EXAMPLE 16 55

2,3,4,10-Tetrahydro-3,3-dimethyl-10-(4-methylphenyisulphonamido)-10phenylpy rimido[1,2-alin- dole Toluene-4-sulphonyl chloride (1.39) was added to the product free base from Example 6 (1.03g) in pyridine (40mi) and triethylamine (1 m]) with stirring and, after 1.5 hour, the solution was evaporated in vacuo, The residue was dissolved in dichloromethane (50 mi) and the solution 60 washed with water (2 x 100 mi), dried (M9S0j, and evaporated in vacuo to give a red foam (1.829).

The foam crystallised from ethyl acetate as a yellow solid (0.52g) which was purified by recrystallisation from propan-2-ol/di-iso-propyl ether to give the title compound (0.279), m.p.

224-2260. 65 7 GB2191482A 7 Found: C, 69.5: H, 6.25; N, 9.2.

C.6HUN302S.1H20 requires: C, 69.4; H, 6.2; N, 9.3%.

4 The ethyl acetate filtrate was purified by chromatography (A1203; ethyl acetate) to give a second crop of title compound (0.289).

5 EXAMPLE 17

2,3,4, 10-Tetrahydro- 10-ethoxycarbonylamino-3,3-dimethyl- 10phenylpyrimido[1,2alindole Ethyl chloroformate (0.9mi) was added to the product free base from Example 6 (1.329) in pyridine (40 m]) and triethylamine (1 m]) with stirring and, after 2 hours, the solution was evaporated in vacuo. The residue was dissolved in dichloromethane (50 mi) and the solution 10 washed with water (2 x 1 00mi), dried (M9S0j, and evaporated in vacuo to give a red oil (1.599). The residue was purified by chromatography to give a yellow oil (0.629) which slowly crystallised on trituration with ether as the title compound (0.29g), m.p. 169-1710. Found: C, 72.4; H, 6. 8; N, 11.4 C22H2,N,O, requires: C, 72.7; H, 6.9; N, 11.6% 15 EXAMPLE 18

10-Acetamido-2,3,4, 10-tetrahydro-3,3-diemthyl- 10-phenylpyrimido[ 1,2alindole Method A 20 The product free base from Example 6 (0.0939) was dissolved in acetic anhydride (10 mi) and after 41 hours the solution was evaporated in vacuo. The residue was dissolved in dichlorometh 2 ane (50 m]) and the solution washed with saturated aqueous sodium bicarbonate (50m[) and water (50 m]), dried (MgSOJ, and evaporated in vacuo to give the title compound free base (0.1069), m.p. 233-235'. 25 Method 8 A solution of the product free base from Example 6 (0.1379) and triethylamine (0. '1 mi) in pyridine (5 m]) was treated dropwise with acetyl chloride (0. 1 mi) and after 2 hours evaporated in vacuo. The residue was partioned between water (50 mi) and dichloromethane (70 mi) and 30 the organic phase washed with brine (50 H), dried (M9S0j, and evaporated in vacuo. The residue was azeotroped in vacuo with toluene to give the title compound free base (0.039) as a light yellow solid, m.p. 230-232'.

Claims (29)

CLAIMS 35

1. A compound of the general formula (1) R1 R NR5R6 N 1 - 40 N X R2 45 or a pharmaceutical ly acceptable acid addition salt thereof, wherein R represents alkyl or a mono- or bicyclic aryl radical, R' and R2 which may be the same or different each represent hydrogen, hydroxy], lower alkyl, lower alkoxy, halo(lower)aikyl, halogen, amino or mono- or di(lower)aikylamino, X represents -CH2CR3R4CH2- or -(CHI)4- where R3 and R4 each indepen dently represent hydrogen or lower alkyl or R3 and R4 together with the carbon atom to which 50 they are attached represent a 5, 6 or 7 membered carbocyclic ring and R5 represents acyl and R6 represents hydrogen or R5 and R6 each independently represent hydrogen or lower alkyl.

2. A compound as claimed in claim 1 wherein R is phenyl optionally substituted by one or more halogen, lower alkyl, lower alkoxy or halo(lower) alkyl substituents.

3. A compound as claimed in claim 1 or 2 wherein X represents -CH2CR3R4CH, - wherein R3 55 and R4 are both hydrogen or both (lower)aikyl or R3 and R4 together with the carbon atom to which they are attached represent a cycloalkyl radical containing 5 to 7 carbon atoms.

4. A compound as claimed in any one of claims 1 to 3 wherein R' and R6 are both hydrogen or R 6 is hydrogen and R5 is an acyl group selected from (lower) alkoxycarbonyl; (lower)alkyl-, ary]- or aryi(iower)aikylsulphonyl; lower alkyl-, ary]- or aryi(iower)aikyisulphonylcarbamoyi; (lower)alkyl60 carbonyl; arylcarbonyl or a ryl (lower) alkylearbony].

5. 10-Acetamido-10-(3-chlorophenyi)-2,3,4,10-tetrahydropyrimido[1,2alindole or a pharmaceu tically acceptable acid addition salt thereof.

6. 10-Amino-10-(3-chlorophenyi)-2,3,4,10-tetrahydro-pyrimido[1,2-a]indole or a pharmaceuti cally acceptable acid addition salt thereof. 65 8 GB2191482A 8

7. 10-Acetamido-2,3,4,10-tetrahydro-10-phenylpyrimido-[1,2-alindole or a pharmaceutically ac ceptable acid addition salt thereof.

8. 10-Amino-10-phenyi-2,3,4,10-tetrahydropyrimido-[1,2-alindole or a pharmaceutically ac ceptable acid addition salt thereof.

9. 10-Acetamido-2,3,4,10-tetrahydro-3,3-dimethyi-10-phenylpyrimido[1,2alindole or a phar- 5 maceutically acceptable acid addition salt thereof.

10. 10-Amino-2,3,4,10-tetrahydro-3,3-dimethyi-10-phenylpyrimido[1,2alindole or a pharma ceutically acceptable acid addition salt thereof.

11. 1 0-Acetamido-2,3,4, 1 0-tetrahydro- 1 0-methylpyrimido-[ 1,2alindole or a pharmaceutically acceptable acid addition salt thereof. 10

12. 2,3,4,10-Tetrahydro-3,3-dimethyi-10-methyisulphonylamino-10phenylpyrimido[1,2-alindole or a pharmaceutically acceptable acid addition salt thereof.

13. 10'-Acetamido-2',3',4',10'-tetrahydro-10'-phenyispiro[cyclohexane-1, 3'-pyrim ido[1,2-alindole] or a pharmaceutically acceptable acid addition salt thereof.

14. 11 -Acetamido-2,3,4, 1 0-tetrahydro- 11 -phenyl- 11 H-[ 1, 31diazepino[ 1,2-alindole or a pharma- 15 ceutically acceptable acid addition salt thereof.

15. 1 0-Acetamido-2,3,4, 1 0-tetra hydro- 1 0-(2-naphthyi)-pyrim ido[ 1,2a]indole or a pharmaceutically acceptable acid adition salt thereof.

16. 10'-Acetamido-2',3',4',10-tetrahydro-10'-phenyispiro[cyclopentane-1, 3'-pyrim ido[1,2-alindo- le] or a pharmaceutically acceptable acid addition salt thereof. 20

17. 10-Butanamido-2,3,4,10-tetrahydro-3,3-dimethyl-10-phenylpyrimido[1,2alindol e or a phar maceutically acceptable acid addition salt thereof.

18. 2,3,4,10-Tetrahydro-3,3-dimethyi-10-[3-(4methylphenyisulphonyi)ureido]10-ph enylpyri- mido[1,2-alindole or a pharmaceutically acceptable acid addition salt thereof.

19. 10-Benzamido-2,3,4,10-tetrahydro-3,3-dimethyi-10-phenylpyrimido[1,2alindole or a phar- 25 maceutically acceptable acid addition salt thereof.

20. 2,3,4,10-Tetrahydro-3,3-dimethyi-10-(4-methylphenyisulphonamido)-10phenylpy ri- mido[1,2-a]indole or a pharmaceutically acceptable acid addition salt thereof.

21. 2,3,4,10-Tetrahydro-10-ethoxycarbonylamino-3,3-dimethyi-10phenyipyrimido[1, 2-a]indole or a pharmaceutically acceptable acid addition salt thereof. 30

22. A process for preparing a compound claimed in claim 1 in which R5 represents a (lower)aikylearbonyl group and R6 represents hydrogen which comprises reacting a tertiary alco hol of general formula (11) R1 R OH 35 un 1 N 1\1 X 40 R2 (wherein X, R, R' and R 2 are as defined in claim 1) or an acid addition salt thereof, with an organic nitrile of general formula 45 R 7 M (111) (where R7 represents lower alkyl).

23. A process for preparing a compound claimed in claim 1 in which R5 and R6 are both hydrogen which comprises hydrolysing a compound claimed in claim 1 in which R5 represents 50 (lower)aikylcarbonyl and R6 represents hydrogen.

24. A process for preparing a compound claimed in claim 1 in which R5 is (lower)aikyl and R6 is hydrogen or lower alkyi or in which R.' is acyl and R6 is hydrogen which comprises N alkylating or acylating a compound claimed in claim 1 in which R' and R 6 are both hydrogen.

25. A process for preparing a compound claimed in claim 1 substantially as hereinbefore 55 described with reference to any one of Examples 1 to 17, 18A and 1813.

26. A compound as claimed in claim 1 whenever prepared by a process claimed in any one of claims 22 to 25.

27. A pharmaceutical composition comprising a compound claimed in any one of claims 1 to 21 and 26 in association with a pharmaceutically acceptable carrier. 60

28. A compound as claimed in any one of claims 1 to 21 and 26 for use as a pharmaceuti cal.

29. A compound as claimed in any one of claims 1 to 21 and 26 for use as a hypoglycae mic.

9 GB2191482A 9 Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd, Dd 8991685, 1987. Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1 AY, from which copies may be obtained.

Y